Radiopharmaceuticals Treatment of Prostate Cancer (Xofigo)
- United Lincolnshire Teaching Hospitals NHS Trust
- East Midlands
- Direct award
- 31 December 2025 to 30 December 2027
Provision of Xofigo (radium-223 dichloride) for the treatment of patients with prostate cancer. This is a pharmaceutical supply contract for a specific therapeutic agent, managed as a direct procurement for clinical use.
- Awarded value
- £106k
- As published
- Published
- 11 March 2026
- Contract length
- 24 months
- Ends 30 December 2027